Acurx PharmaceuticalsACXP
13F holders, Q4 2025 (December 31)18holders +2
7new positions
5sold out
1famous investor
$2.49avg. 13F price*
At the end of Q4 2025, 18 institutions reported holding Acurx Pharmaceuticals Inc. (ACXP) in their 13F filings, up 2 from Q3 2025. 7 opened new positions and 5 sold out. The largest holders were Millennium Management ($103K), Vanguard Group Inc. ($58K) and Prospect Financial Services LLC ($49K). One famous investor held it Israel Englander (0.0% of Millennium Management's portfolio).
- Company
- Acurx Pharmaceuticals Inc.
- CUSIP
- 00510M203
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 7 | $267K |
| Exits | 5 | $115K |
All 13F filers, Q3 2025 → Q4 2025: 110,348 shares bought and 27,532 shares sold, net +82,816 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 18 holders
| Millennium Management | 0.00% | New | 41,427 | $103K |
| Vanguard Group Inc. | 0.00% | New | 23,280 | $58K |
| Prospect Financial Services LLC | 0.03% | Reduce -0.3% | 19,833 | $49K |
| Northern Trust Corp. | 0.00% | New | 16,914 | $42K |
| Geode Capital Management, LLC | 0.00% | New | 12,417 | $31K |
| Jane Street Group, LLC | 0.00% | New | 10,743 | $27K |
| Morgan Stanley | 0.00% | Add +22.4% | 6,500 | $16K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +167.9% | 2,885 | $7K |
| Wells Fargo & Company | 0.00% | New | 2,300 | $6K |
| Lanark Financial, Inc. | 0.00% | No change | 1,500 | $4K |
| Group One Trading LLC | 0.00% | Reduce -5.0% | 283 | $705 |
| Cornerstone Planning Group LLC | 0.00% | Add +149.3% | 167 | $433 |
| UBS Group AG | 0.00% | New | 169 | $420 |
| Osaic Holdings, Inc. | 0.00% | Reduce -58.7% | 100 | $249 |
| BlackRock, Inc. | 0.00% | No change | 60 | $149 |
| Bank of America Corp. | 0.00% | Reduce -76.1% | 17 | $42 |
| SBI Securities Co., Ltd. | 0.00% | No change | 13 | $32 |
| Citigroup Inc. | 0.00% | Reduce -99.8% | 1 | $2 |
"% of holder's portfolio" is ACXP's weight in each manager's 13F, not the share of Acurx Pharmaceuticals Inc. the manager owns.